English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Chronic granulomatous disease (CGD) is the most common type of primary innate immune deficiency caused by defects in the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase enzyme in the neutrophils. (1) It’s considered as a fatal granulomatous disease of childhood as most patients with CGD die by 10 years of age. (2) Any mutation at one of the genes encoding for glycoproteins that are forming the five subunits of the NADPH oxidase enzyme leads to CGD. If the mutation leaves some residual NADPH oxidase activity intact the clinical expression of the disease is attenuated and prognosis is better. (3) CGD can be treated by conventional treatment, stem cell transplantation or genetic therapy. (4) The (DHR) test was approved to be the gold standard for diagnosis of CGD. (5)

STUDY OF THE EFFECT OF ACTIVE INFECTIONS ON DIHYDRORHODAMINE (DHR) TEST IN CHRONIC GRANULOMATOUS DISEASE PATIENTS (CGD)